Mosunetuzumab Step-Up Dosing for Elderly Lymphoma Patients
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Elderly patients with relapsed and/or refractory non-Hodgkin's lymphoma, particularly those with follicular lymphoma or diffuse large B cell lymphoma, face challenges in treatment due to increased comorbidities and reduced immune function, with existing bispecific antibody therapies often limited by toxicity and reduced efficacy after prior anti-CD20 antibody exposure.
Innovation Solution
A dosing regimen for the anti-CD20/anti-CD3 bispecific antibody mosunetuzumab involving a step-up, fractionated dosing cycle with higher loading doses followed by base doses, administered intravenously over multiple cycles, specifically tailored for elderly subjects aged 65 years or older, to enhance treatment efficacy while minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bispecific antibody therapy is administered to elderly patients with relapsed and/or refractory non-Hodgkin's lymphoma, then treatment efficacy is improved, but toxicity and serious adverse events increase
Solution Approach 1:
The dosing regimen segments the total dose into multiple administrations across different cycles. The first dosing cycle includes three separate doses (C1D1, C1D2, C1D3) administered at different time points, while subsequent cycles have single doses (C2D1, C3D1). This segmentation allows the immune system to process and tolerate each individual dose better while achieving cumulative therapeutic effect, thereby reducing acute toxicity in elderly patients.
Solution Approach 2:
The dosing regimen dynamically adjusts the dose amount based on the dosing cycle number and patient response. Loading doses (C1D3, C2D1) are higher than base doses (C3D1), and the regimen adapts to patient tolerance and efficacy markers. This dynamic approach optimizes the balance between achieving sufficient immune activation for efficacy and preventing excessive toxicity in the vulnerable elderly population.
2Productivity
If higher loading doses are administered to achieve rapid response, then objective response rate improves, but cytokine release syndrome severity increases
Solution Approach 1:
The loading dose is segmented into multiple administrations rather than a single large dose. The first dosing cycle comprises three separate doses (C1D1 at 1 mg, C1D2 at 2 mg, C1D3 at 60 mg) given at different time points, which distributes the immune stimulation over time. This reduces the peak cytokine release burden on the patient's system while still achieving rapid and sustained objective response.
Solution Approach 2:
The dosing regimen employs periodic administration with specific intervals between doses. The first three doses are administered at different time points within the first cycle, followed by single doses in subsequent cycles. This periodic action pattern allows the body to gradually adapt to increasing immunostimulation, preventing overwhelming cytokine release while maintaining high response rates.
3Device complexity
If standard dosing regimens are used in elderly patients, then treatment protocol simplicity is maintained, but benefit-risk profile deteriorates
Solution Approach 1:
The dosing regimen segments treatment into distinct phases with different dosing patterns. The first dosing cycle has three separate doses (C1D1, C1D2, C1D3), while subsequent cycles have single doses (C2D1, C3D1). This segmentation creates a structured approach that simplifies clinical implementation through clear phase-based guidelines while optimizing the benefit-risk profile for elderly patients by reducing cumulative toxicity.
Solution Approach 2:
The dosing regimen changes key parameters including dose amount, dosing frequency, and timing based on the cycle number and patient response. Loading doses (C1D3, C2D1) are higher than base doses (C3D1), and the regimen adapts to patient tolerance and efficacy markers. These parameter changes optimize the benefit-risk profile by tailoring the regimen to individual patient needs while maintaining overall protocol simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The regimen effectively treats relapsed and refractory non-Hodgkin's lymphoma in elderly patients with a favorable benefit-risk profile, achieving high objective response rates, complete response rates, and prolonged progression-free survival with reduced serious adverse events and cytokine release syndrome.
Implementation Method 1
the bound cytotoxic cell destroys the juxtaposed bound cancer cell via an immunological synapse
Data Source
AI summary
The present invention relates to the treatment of elderly subjects (e.g., subjects aged 65 years or older) having relapsed and/or refractory (R/R) non-Hodgkin's lymphoma (NHL). More specifically, the invention pertains to the treatment of subjects having an R/R NHL by intravenous administration of mosunetuzumab.